Ahmed T. Elhendawy

Dr. Ahmed T. Elhendawy

Faculty of Engineering Technology,, ElSewedy University of Technology, Cairo, Al Qāhirah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2025 in SLAS Technology
Verified
Journal Article
Open access
Mohammad AatifMohammad Aatif
Mohammad Aatif
MAMohamed S. AboHoussien
Mohamed S. AboHoussien
Ahmed T. ElhendawyAhmed T. Elhendawy
Ahmed T. Elhendawy
Ghazala MuteebGhazala Muteeb
Ghazala Muteeb
EFEduardo Libao Fabella
Eduardo Libao Fabella
Doaa S. R. KhafagaDoaa S. R. Khafaga
Doaa S. R. Khafaga
Prostate cancer remains one of the leading causes of cancer-related illness and death in men globally. Despite advancements in diagnostics and traditional therapies, significant challenges such as drug resistance, systemic toxicity, and restricted specificity persist in impeding successful management. In recent years, nanotechnology has emerged as a revolutionary method in cancer treatment, offering targeted drug delivery, enhanced bioavailability, and reduced off-target side effects. Eco-friendly or green-synthesized nanomaterials have gained significant attention due to their biocompatibility, sustainability, and reduced environmental impact. This review delineates the present state of prostate cancer treatment and the constraints of traditional pharmacological approaches. We subsequently investigate the burgeoning role of nanomedicine in addressing these difficulties, focusing specifically on eco-friendly nanomaterials synthesized from plant extracts, microbial systems, and natural polymers. These biosynthesized nanoparticles (NPs) provide dual benefits: medicinal effectiveness and diminished environmental impact, consistent with the tenets of green chemistry and sustainable medicine. Additionally, we examine diverse drug delivery systems employing green NPs for prostate cancer, including liposomes, polymeric NPs, and metal-based systems synthesized through environmentally friendly methods. Recent in vitro and in vivo research is rigorously examined to assess the clinical potential of these methodologies. The review identifies significant translational hurdles, such as large-scale repeatability, regulatory constraints, and stability concerns, while proposing potential future approaches to enhance the therapeutic application of eco-friendly nanomedicine in prostate cancer treatment.

30 March 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Hagar Sabry El-HemaHagar Sabry El-Hema
Hagar Sabry El-Hema
MAMarwa A. Abed
Marwa A. Abed
MHMohamed A. Hawata
Mohamed A. Hawata
ENEman Nossier
Eman Nossier
NANajla Altwaijry
Najla Altwaijry
AAAdel A.-H. Abdel-Rahman
Adel A.-H. Abdel-Rahman
Background: Cancer patients are highly susceptible to microbial infections due to immune suppression, necessitating therapeutic strategies that integrate anticancer efficacy with effective antimicrobial intervention. Chalcone-derived nitrogen-fused heterocycles represent a promising platform for developing multi-target agents with relevance to antimicrobial drug delivery, particularly for localized infections. Methods: A series of chalcone-based pyrazoline-thiadiazole nitrogen-fused azole hybrids was synthesized via thiosemicarbohydrazide-functionalized intermediates and fully characterized. Antiproliferative activity was evaluated against MCF-7, HepG-2, HeLa, and HCT-116 cell lines, alongside selectivity toward WI-38 normal fibroblasts. Antibacterial, antibiofilm, and in vivo efficacy were assessed against methicillin-resistant Staphylococcus aureus (MRSA USA300) and Acinetobacter baumannii AB5057. Mechanistic investigations included cell-cycle analysis, apoptosis assays, ERK2, RIPK3, p53, BAX/Bcl-2 quantification, DNA gyrase inhibition, molecular docking, molecular dynamics simulations, and density functional theory calculations. Results: Compound 13 exhibited potent cytotoxicity, particularly against MCF-7 (IC50 = 3.87 ± 0.2 µM), outperforming doxorubicin (IC50 = 4.17 ± 0.2 µM), with high selectivity indices (SI = 10.7 for MCF-7). Mechanistically, compound 13 induced G2/M arrest (40.16% vs. 14.15% control), increased apoptosis to 32.89%, up-regulated ERK2 (3.17-fold), RIPK3 (11.97-fold), and p53 (3.54-fold), and markedly increased the BAX/Bcl-2 ratio (~42-fold). Compounds 7 and 13 displayed bactericidal activity against MRSA and A. baumannii (MIC/MBC = 10 mg/mL), potent antibiofilm effects, and significant in vivo efficacy in an MRSA skin infection model. Compound 13 reduced bacterial load by ~5 log units, outperforming vancomycin. DNA gyrase inhibition (IC50 = 17.10 ± 0.17 µM) and computational studies supported target engagement. Conclusions: Pyrazoline-thiadiazole-based nitrogen-fused azole hybrids, particularly compound 13, demonstrated quantifiable anticancer and antimicrobial efficacy with strong in vivo validation, supporting their potential as multi-target candidates relevant to antimicrobial drug delivery in infection-prone cancer patients.

24 January 2026 in Journal of Molecular Structure
Verified
Journal Article
Closed access
Hagar Sabry El-HemaHagar Sabry El-Hema
Hagar Sabry El-Hema
HFHadeer M. El Fekey
Hadeer M. El Fekey
MHMohamed A. Hawata
Mohamed A. Hawata
MHModather F. Hussein
Modather F. Hussein
Ahmed T. ElhendawyAhmed T. Elhendawy
Ahmed T. Elhendawy
AAAdel A.H. Abdel-Rahman
Adel A.H. Abdel-Rahman

2 May 2026 in Journal of Molecular Structure
Verified
Journal Article
Closed access
Hagar Sabry El-HemaHagar Sabry El-Hema
Hagar Sabry El-Hema
AAAdel Ahmed
Adel Ahmed
AWAya Waheed
Aya Waheed
MHMohamed A. Hawata
Mohamed A. Hawata
MHModather F. Hussein
Modather F. Hussein
AAAdel A.-H. Abdel-Rahman
Adel A.-H. Abdel-Rahman

27 May 2026 in Bioorganic Chemistry
Verified
Journal Article
Closed access
Hagar Sabry El-HemaHagar Sabry El-Hema
Hagar Sabry El-Hema
RERasha A.-S. El-Ghorab
Rasha A.-S. El-Ghorab
MHMohamed A. Hawata
Mohamed A. Hawata
ENEman S. Nossier
Eman S. Nossier
MHModather F. Hussein
Modather F. Hussein
AAAdel A.-H. Abdel-Rahman
Adel A.-H. Abdel-Rahman

8 May 2026 in Bioorganic Chemistry
Verified
Journal Article
Closed access
HAHeba F. Ashour
Heba F. Ashour
AYAsmaa yassen
Asmaa yassen
KSKhalid B. Selim
Khalid B. Selim
MEMagda A.A. El-Sayed
Magda A.A. El-Sayed
Ahmed T. ElhendawyAhmed T. Elhendawy
Ahmed T. Elhendawy
HEHosam A. Elshihawy
Hosam A. Elshihawy